ADCETRIS

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, South Africa, Spain, Turkey, UK.

Active ingredients

The drug ADCETRIS contains one active pharmaceutical ingredient (API):

1	Brentuximab vedotin UNII 7XL5ISS668 - BRENTUXIMAB VEDOTIN
	Brentuximab vedotin is an ADC that delivers an antineoplastic agent that results in apoptotic cell death selectively in CD30-expressing tumour cells. Because of the CD30-targeted mechanism of action brentuximab vedotin is able to overcome chemo-resistance as CD30 is consistently expressed in patients who are refractory to multi-agent chemotherapy, irrespective of prior transplant status.
	Read more about Brentuximab vedotin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ADCETRIS Powder for concentrate for solution	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX05	Brentuximab vedotin	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10166C, 10171H, 10172J, 10180T, 11067L, 11073T, 11079D, 11080E, 11086L, 11087M, 11089P, 11096B, 11651F, 11660Q, 11661R, 11664X
BR	Câmara de Regulação do Mercado de Medicamentos	501115010024502
CA	Health Products and Food Branch	02401347
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	18-MBE-1214
EE	Ravimiamet	1597967
ES	Centro de información online de medicamentos de la AEMPS	112794001, 112794001IP
FI	Lääkealan turvallisuus- ja kehittämiskeskus	095175
FR	Base de données publique des médicaments	68438457
GB	Medicines & Healthcare Products Regulatory Agency	215727
HK	Department of Health Drug Office	63483
IL	מִשְׂרַד הַבְּרִיאוּת	7193
JP	医薬品医療機器総合機構	4291425D1021
LT	Valstybinė vaistų kontrolės tarnyba	1068355, 1082316
NL	Z-Index G-Standaard, PRK	103993
PL	Rejestru Produktów Leczniczych	100285152
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W61128001
SG	Health Sciences Authority	14477P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699456790058
US	FDA, National Drug Code	51144-050
ZA	Health Products Regulatory Authority	48/26/0433